MOR MorphoSys AG

28.74
-0.2  -1%
Previous Close 28.94
Open 28.9
Price To Book 7.45
Market Cap 3,641,712,307
Shares 126,712,328
Volume 236,251
Short Ratio
Av. Daily Volume 83,491
Stock charts supplied by TradingView

NewsSee all news

  1. Markus Enzelberger, Chief Scientific Officer of MorphoSys, Announces His Departure

    PLANEGG/MUNICH, GERMANY / ACCESSWIRE / November 20, 2019 / MorphoSys AG ((FSE:MOR, Prime Standard Segment, MDAX &, TecDAX, NASDAQ:MOR) today announced that Dr. Markus Enzelberger, the company's Chief Scientific

  2. MorphoSys Continues to Build Commercial Presence by Opening new U.S. Headoffice

    PLANEGG/MUNICH, GERMANY and BOSTON MA / ACCESSWIRE / November 15, 2019 / MorphoSys ((FSE: MOR, Prime Standard Segment, MDAX &, TecDAX, NASDAQ:MOR) announced today the opening of its new U.S. headoffice. Based in

  3. Results for Bimagrumab in Obesity and Type 2 Diabetes Presented by MorphoSys's Partner

    PLANEGG/MUNICH, GERMANY / ACCESSWIRE / November 11, 2019 / MorphoSys AG ((FSE: MOR, Prime Standard Segment, MDAX &, TecDAX, NASDAQ:MOR) announced today that its licensee Novartis presented phase 2 results for

  4. MorphoSys to Present Data on Tafasitamab at ASH 2019 Meeting

    PLANEGG/MUNICH, GERMANY / ACCESSWIRE / November 6, 2019 / MorphoSys AG ((FSE:MOR, Prime Standard Segment, MDAX &, TecDAX, NASDAQ:MOR) today announced presentation of so far unpublished data on tafasitamab, its

  5. MOR106 clinical development in atopic dermatitis stopped for futility

    20.15 CET; regulated information - MorphoSys AG ((FSE: MOR, Prime Standard Segment, TecDAX, NASDAQ:MOR) and Galapagos NV ((Euronext &, NASDAQ:GLPG) today announced the end of the clinical development program of MOR106

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 3 ContRAst trial initiation announced July 3, 2019.
Otilimab (MOR103/GSK3196165)
Rheumatoid Arthritis
Phase 2 trial halted due to futility - October 28, 2019.
MOR106 IGUANA
Atopic dermatitis
Phase 3 dosing has commenced - noted April 30, 2019.
TJ202/MOR202
Multiple Myeloma (MM) - second line
Phase 2 data to be presented at ASH December 7, 2019 at 9am EST.
MOR208 + idelalisib (COSMOS)
Chronic Lymphocytic Leukemia
Phase 3 futility analysis passed November 18, 2019. Top-line data due 1Q 2022.
Bendamustine + MOR208 - B-MIND
Relapsed or refractory diffuse large B cell lymphoma (r/r DLBCL)
Rolling BLA filing has been initiated. To be completed by end of 2019.
Lenalidomide + MOR208 - L-MIND
Relapsed or refractory diffuse large B cell lymphoma
Phase 3 enrollment has commenced - noted June 14, 2018.
Gantenerumab
Early Alzheimer's disease
Phase 2/3 trial initiation announced July 11, 2018.
Guselkumab (GALAXI 1)
Crohn's disease
Phase 2 trial initiation announced November 19, 2018.
Guselkumab (NOVA)
Hidradenitis Suppurativa
Phase 3 primary endpoint met - December 12, 2018.
Guselkumab vs Cosentyx - ECLIPSE
Psoriasis
Phase 2a initiation announced January 17, 2019.
Guselkumab
Ulcerative colitis
Approval announced February 27, 2019.
Guselkumab
Plaque psoriasis
Phase 1b trial to be initiated 4Q 2019.
MOR208 tafasitamab
Front-line diffuse large B cell lymphoma (DLBCL)
Phase 1/2 trial to be initiated 4Q 2019.
MOR202
Membranous nephropathy
sBLA filing announced September 16, 2019.
Guselkumab
Psoriatic Arthritis
Phase 2b data due late-2019 or early 2020.
BPS-804 (setrusumab)
Osteogenesis Imperfecta
Phase 1 data to be presented at ASH December 8, 2019 at 9am.
Tafasitamab - First-MIND
Diffuse Large B-cell Lymphoma

Latest News

  1. Markus Enzelberger, Chief Scientific Officer of MorphoSys, Announces His Departure

    PLANEGG/MUNICH, GERMANY / ACCESSWIRE / November 20, 2019 / MorphoSys AG ((FSE:MOR, Prime Standard Segment, MDAX &, TecDAX, NASDAQ:MOR) today announced that Dr. Markus Enzelberger, the company's Chief Scientific

  2. MorphoSys Continues to Build Commercial Presence by Opening new U.S. Headoffice

    PLANEGG/MUNICH, GERMANY and BOSTON MA / ACCESSWIRE / November 15, 2019 / MorphoSys ((FSE: MOR, Prime Standard Segment, MDAX &, TecDAX, NASDAQ:MOR) announced today the opening of its new U.S. headoffice. Based in

  3. Results for Bimagrumab in Obesity and Type 2 Diabetes Presented by MorphoSys's Partner

    PLANEGG/MUNICH, GERMANY / ACCESSWIRE / November 11, 2019 / MorphoSys AG ((FSE: MOR, Prime Standard Segment, MDAX &, TecDAX, NASDAQ:MOR) announced today that its licensee Novartis presented phase 2 results for

  4. MorphoSys to Present Data on Tafasitamab at ASH 2019 Meeting

    PLANEGG/MUNICH, GERMANY / ACCESSWIRE / November 6, 2019 / MorphoSys AG ((FSE:MOR, Prime Standard Segment, MDAX &, TecDAX, NASDAQ:MOR) today announced presentation of so far unpublished data on tafasitamab, its

  5. MOR106 clinical development in atopic dermatitis stopped for futility

    20.15 CET; regulated information - MorphoSys AG ((FSE: MOR, Prime Standard Segment, TecDAX, NASDAQ:MOR) and Galapagos NV ((Euronext &, NASDAQ:GLPG) today announced the end of the clinical development program of MOR106

  6. MOR106 clinical development in atopic dermatitis stopped for futility

    20.15 CET; regulated information - MorphoSys AG ((FSE: MOR, Prime Standard Segment, TecDAX, NASDAQ:MOR) and Galapagos NV ((Euronext &, NASDAQ:GLPG) today announced the end of the clinical development program of MOR106

  7. MOR106 clinical development in atopic dermatitis stopped for futility

    20.15 CET; regulated information - MorphoSys AG ((FSE: MOR, Prime Standard Segment, TecDAX, NASDAQ:MOR) and Galapagos NV ((Euronext &, NASDAQ:GLPG) today announced the end of the clinical development program of MOR106

  8. MOR106 clinical development in atopic dermatitis stopped for futility

    20.15 CET; regulated information - MorphoSys AG ((FSE: MOR, Prime Standard Segment, TecDAX, NASDAQ:MOR) and Galapagos NV ((Euronext &, NASDAQ:GLPG) today announced the end of the clinical development program of MOR106

  9. MOR106 clinical development in atopic dermatitis stopped for futility

    20.15 CET; regulated information - MorphoSys AG ((FSE: MOR, Prime Standard Segment, TecDAX, NASDAQ:MOR) and Galapagos NV ((Euronext &, NASDAQ:GLPG) today announced the end of the clinical development program of MOR106

  10. MOR106 clinical development in atopic dermatitis stopped for futility

    20.15 CET; regulated information - MorphoSys AG ((FSE: MOR, Prime Standard Segment, TecDAX, NASDAQ:MOR) and Galapagos NV ((Euronext &, NASDAQ:GLPG) today announced the end of the clinical development program of MOR106

  11. MOR106 clinical development in atopic dermatitis stopped for futility

    20.15 CET; regulated information - MorphoSys AG ((FSE: MOR, Prime Standard Segment, TecDAX, NASDAQ:MOR) and Galapagos NV ((Euronext &, NASDAQ:GLPG) today announced the end of the clinical development program of MOR106

  12. MOR106 clinical development in atopic dermatitis stopped for futility

    20.15 CET; regulated information - MorphoSys AG ((FSE: MOR, Prime Standard Segment, TecDAX, NASDAQ:MOR) and Galapagos NV ((Euronext &, NASDAQ:GLPG) today announced the end of the clinical development program of MOR106

  13. MorphoSys and I-Mab Biopharma Announce IND Clearance to Initiate Clinical Trials of MOR202/TJ202 for the Treatment of Multiple Myeloma in Mainland China

    PLANEGG/MUNICH, GERMANY and SHANGHAI, CHINA / ACCESSWIRE / October 14, 2019 / MorphoSys AG ((FSE:MOR, Prime Standard Segment, MDAX &, TecDAX, NASDAQ:MOR) and I-Mab Biopharma (I-Mab) announced today that I-Mab has

  14. I-Mab Biopharma and MorphoSys Announce IND Clearance to Initiate Clinical Trials of TJ202/MOR202 for the Treatment of Multiple Myeloma in Mainland China

    SHANGHAI, Oct. 14, 2019 /PRNewswire/ -- I-Mab Biopharma ("I-Mab"), a China and U.S.-based clinical stage biopharmaceutical company exclusively focused on the discovery and development of novel or highly

  15. MorphoSys to Present at Upcoming Investor Conferences

    PLANEGG/MUNICH, GERMANY / ACCESSWIRE / September 18, 2019 / MorphoSys AG ((FSE: MOR, Prime Standard Segment, MDAX &, TecDAX, NASDAQ:MOR) will present at the following conferences:Baader Investment ConferenceDate:

  16. MorphoSys's Licensee Janssen Submits Biologics License Application to U.S. FDA of Tremfya(R) (Guselkumab) for Treatment of Adults with Active Psoriatic Arthritis

    MorphoSys's Licensee Janssen Submits Biologics License Application to U.S. FDA of Tremfya(R) (Guselkumab) for Treatment of Adults with Active Psoriatic ArthritisPLANEGG / MUNICH, GERMANY / ACCESSWIRE / September